PURPOSE: To investigate if opposed-phase T1-weighted and fat-suppressed T2-weighted liver signal intensity (SI) loss and visceral fat measurement at magnetic resonance (MR) imaging and body mass index (BMI) are correlated with grade of liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD) or hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-related liver disease. MATERIALS AND METHODS: Committee on Human Research approval and patient consent were obtained for this HIPAA-compliant study. Fifty-two patients (15 men, 37 women) with NAFLD (n = 29) or HCV and HIV-related liver disease (n = 23) underwent prospective contemporaneous MR imaging and liver biopsy. Liver SI loss was measured on opposed-phase T1-weighted and fat-suppressed T2-weighted MR images. Visceral fat area was measured at three levels on water-suppressed T1-weighted MR images (n = 44). Spearman rank correlation coefficients and recursive partitioning were used to examine correlations. RESULTS: Histopathologic liver steatosis correlated well with liver SI loss on opposed-phase T1-weighted MR images (rho = 0.78), fat-suppressed T2-weighted MR images (rho = 0.75), and average visceral fat area (rho = 0.77) (all P < .01) but poorly with BMI (rho = 0.53, P < .01). Liver SI losses on opposed-phase T1-weighted MR imaging of less than 3%, at least 3% but less than 35%, at least 35% but less than 49%, and at least 49% corresponded to histopathologic steatosis grades of 0 (n = 16 of 17), 1 (n = 11 of 16), 2 (n = 7 of 13), and 3 (n = 5 of 6), respectively. A visceral fat area of greater than or equal to 73.8 cm(2) was associated with the presence of histopathologic steatosis in 41 of 44 patients. CONCLUSION: Liver SI loss on opposed-phase T1-weighted MR images and visceral fat area may be used as biomarkers for the presence of liver steatosis and appear to be superior to BMI. (c) RSNA, 2008.
PURPOSE: To investigate if opposed-phase T1-weighted and fat-suppressed T2-weighted liver signal intensity (SI) loss and visceral fat measurement at magnetic resonance (MR) imaging and body mass index (BMI) are correlated with grade of liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD) or hepatitis C virus (HCV) and human immunodeficiency virus (HIV)-related liver disease. MATERIALS AND METHODS: Committee on Human Research approval and patient consent were obtained for this HIPAA-compliant study. Fifty-two patients (15 men, 37 women) with NAFLD (n = 29) or HCV and HIV-related liver disease (n = 23) underwent prospective contemporaneous MR imaging and liver biopsy. Liver SI loss was measured on opposed-phase T1-weighted and fat-suppressed T2-weighted MR images. Visceral fat area was measured at three levels on water-suppressed T1-weighted MR images (n = 44). Spearman rank correlation coefficients and recursive partitioning were used to examine correlations. RESULTS: Histopathologic liver steatosis correlated well with liver SI loss on opposed-phase T1-weighted MR images (rho = 0.78), fat-suppressed T2-weighted MR images (rho = 0.75), and average visceral fat area (rho = 0.77) (all P < .01) but poorly with BMI (rho = 0.53, P < .01). Liver SI losses on opposed-phase T1-weighted MR imaging of less than 3%, at least 3% but less than 35%, at least 35% but less than 49%, and at least 49% corresponded to histopathologic steatosis grades of 0 (n = 16 of 17), 1 (n = 11 of 16), 2 (n = 7 of 13), and 3 (n = 5 of 6), respectively. A visceral fat area of greater than or equal to 73.8 cm(2) was associated with the presence of histopathologic steatosis in 41 of 44 patients. CONCLUSION:Liver SI loss on opposed-phase T1-weighted MR images and visceral fat area may be used as biomarkers for the presence of liver steatosis and appear to be superior to BMI. (c) RSNA, 2008.
Authors: Piyaporn Limanond; Steven S Raman; Charles Lassman; James Sayre; R Mark Ghobrial; Ronald W Busuttil; Sammy Saab; David S K Lu Journal: Radiology Date: 2004-01 Impact factor: 11.105
Authors: Sherif Saadeh; Zobair M Younossi; Erick M Remer; Terry Gramlich; Janus P Ong; Maja Hurley; Kevin D Mullen; James N Cooper; Michael J Sheridan Journal: Gastroenterology Date: 2002-09 Impact factor: 22.682
Authors: Mustafa R Bashir; Tanya Wolfson; Anthony C Gamst; Kathryn J Fowler; Michael Ohliger; Shetal N Shah; Adina Alazraki; Andrew T Trout; Cynthia Behling; Daniela S Allende; Rohit Loomba; Arun Sanyal; Jeffrey Schwimmer; Joel E Lavine; Wei Shen; James Tonascia; Mark L Van Natta; Adrija Mamidipalli; Jonathan Hooker; Kris V Kowdley; Michael S Middleton; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2018-10-14 Impact factor: 4.813
Authors: Alastair L Young; Dan Wilson; Janice Ward; John Biglands; J Ashley Guthrie; K Rajendra Prasad; Giles J Toogood; Philip J Robinson; J Peter A Lodge Journal: HPB (Oxford) Date: 2012-01-16 Impact factor: 3.647
Authors: A P Rossi; F Fantin; G A Zamboni; G Mazzali; E Zoico; C Bambace; A Antonioli; R Pozzi Mucelli; M Zamboni Journal: Nutr Diabetes Date: 2012-03-05 Impact factor: 5.097
Authors: Michael J House; Eng K Gan; Leon A Adams; Oyekoya T Ayonrinde; Sander J Bangma; Prithi S Bhathal; John K Olynyk; Tim G St Pierre Journal: PLoS One Date: 2013-03-21 Impact factor: 3.240